Drug Transporters: Volume 1: Role and Importance in ADME and Drug Development
Understanding and quantifying the effects of membrane transporters within the human body is essential for modulating drug safety and drug efficacy. In this first volume on Drug Transporters, the current knowledge and techniques in the transporter sciences and their relations to drug metabolism and pharmacokinetics are comprehensively reviewed. The second volume of the book is specifically dedicated to emerging science and technologies, highlighting potential areas for future advances within the drug transporter field.
The topics covered in both volumes ensure that all relevant aspects of transporters are described across the drug development process, from in silico models and preclinical tools through to the potential impact of transporters in the clinic. Contributions are included from expert leaders in the field, at-the-bench industrial scientists, renowned academics and international regulators. Case studies and emerging developments are highlighted, together with the merits and limitations of the available methods and tools, and extensive references to reviews on specific in-depth topics are also included for those wishing to pursue their knowledge further.
As such, this text serves as an essential handbook of information for postgraduate students, academics, industrial scientists and regulators who wish to understand the role of transporters in absorption, distribution, metabolism, and excretion processes. In addition, it is also a useful reference tool on the models and calculations necessary to predict their effect on human pharmacokinetics and pharmacodynamics.
Drug Transporters: Volume 1: Role and Importance in ADME and Drug Development, The Royal Society of Chemistry, 2016.
Download citation file:
Digital access
Print format
Table of contents
-
Chapter 1: Membrane Transporters: Fundamentals, Function and Their Role in ADMEp1-56ByBruno Hagenbuch;Bruno HagenbuchDepartment of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical CenterKansas CityKansas 66160USASearch for other works by this author on:Caroline Rynn;Caroline RynnMetabolism and Pharmacokinetics, Novartis Institutes for Biomedical ResearchPostfach CH-4002 BaselSwitzerlandSearch for other works by this author on:Bruno Stieger;Bruno StiegerUniversity Hospital, Department of Clinical Pharmacology and Toxicology8091 ZürichSwitzerlandSearch for other works by this author on:Glynis NichollsGlynis NichollsIndependent ConsultantWem, ShropshireUKSearch for other works by this author on:
-
Chapter 2: Drug Transporters in the Liver: Their Involvement in the Uptake and Export of Endo- and Xeno-bioticsp57-80ByBruno Stieger;Bruno StiegerUniversity Hospital, Department of Clinical Pharmacology and Toxicology8091 ZürichSwitzerland[email protected]Search for other works by this author on:Bruno HagenbuchBruno HagenbuchDepartment of Pharmacology, Toxicology and Therapeutics, The University of Kansas Medical CenterKansas CityKansas 66160USA[email protected]Search for other works by this author on:
-
Chapter 3: Drug Transporters in the Intestinep81-108ByBente SteffansenBente SteffansenDepartment of Physics, Chemistry and Pharmacy, Faculty of Sciences, University of Southern Denmark55 CampusvejDK-5230 OdenseDenmark[email protected]Search for other works by this author on:
-
Chapter 4: Drug Transporters in the Kidneyp109-150ByGit Weng Chung;Git Weng ChungInstitute for Cellular and Molecular Biosciences, Newcastle University Medical SchoolFramlington PlaceNewcastle upon TyneNE2 4HHUK[email protected]Search for other works by this author on:Sarah Faye Billington;Sarah Faye BillingtonInstitute for Cellular and Molecular Biosciences, Newcastle University Medical SchoolFramlington PlaceNewcastle upon TyneNE2 4HHUK[email protected]Search for other works by this author on:Sarah Elizabeth Jenkinson;Sarah Elizabeth JenkinsonInstitute for Cellular and Molecular Biosciences, Newcastle University Medical SchoolFramlington PlaceNewcastle upon TyneNE2 4HHUK[email protected]Search for other works by this author on:Colin Douglas BrownColin Douglas BrownInstitute for Cellular and Molecular Biosciences, Newcastle University Medical SchoolFramlington PlaceNewcastle upon TyneNE2 4HHUK[email protected]Search for other works by this author on:
-
Chapter 5: Drug Transporters at the Blood–Brain Barrierp151-183ByDavid Dickens;David DickensDepartment of Molecular and Clinical Pharmacology, University of LiverpoolLiverpoolUK[email protected]Search for other works by this author on:Steffen Radisch;Steffen RadischDepartment of Molecular and Clinical Pharmacology, University of LiverpoolLiverpoolUK[email protected]Search for other works by this author on:Munir PirmohamedMunir PirmohamedDepartment of Molecular and Clinical Pharmacology, University of LiverpoolLiverpoolUK[email protected]Search for other works by this author on:
-
Chapter 6: Drug Transporters in the Lung: Expression and Potential Impact on Pulmonary Drug Dispositionp184-228ByCynthia Bosquillon;Cynthia BosquillonSchool of Pharmacy, University of NottinghamUKSearch for other works by this author on:Mark Gumbleton;Mark GumbletonCardiff School of Pharmacy and Pharmaceutical Sciences, University of CardiffUKSearch for other works by this author on:Tove Hegelund-Myrbäck;Tove Hegelund-MyrbäckDrug Metabolism and Pharmacokinetics, Respiratory, Inflammation and Autoimmunity iMed, AstraZeneca R&DGöteborgSwedenSearch for other works by this author on:Takeo Nakanishi;Takeo NakanishiDepartment of Membrane Transport and Biopharmaceutics, Faculty of Pharmacy, Kanasawa UniversityJapanSearch for other works by this author on:Dan Price;Dan PriceCardiff School of Pharmacy and Pharmaceutical Sciences, University of CardiffUKSearch for other works by this author on:Ikumi Tamai;Ikumi TamaiDepartment of Membrane Transport and Biopharmaceutics, Faculty of Pharmacy, Kanasawa UniversityJapanSearch for other works by this author on:Xiao-Hong ZhouXiao-Hong ZhouDepartment of Bioscience, Respiratory, Inflammation and Autoimmunity iMed, AstraZeneca R&DGöteborgSwedenSearch for other works by this author on:
-
Chapter 7: The Characteristics, Validation and Applications of In silico and In vitro Models of Drug Transportersp229-297ByPradeep Sharma;Pradeep SharmaDMPK DSM, iMED and Early DevelopmentAstraZeneca R&D310 Darwin BuildingCambridge Science Park, Milton RoadCambridgeCB4 0WGUK[email protected]Search for other works by this author on:Mohammed I. Atari;Mohammed I. AtariCyprotex Discovery Limited15 Beech LaneMacclesfield, CheshireSK10 2DRUKSearch for other works by this author on:Robert Elsby;Robert ElsbyDMPK DSM, iMED and Early DevelopmentAstraZeneca R&DAlderley ParkMacclesfield, CheshireSK10 4TGUKSearch for other works by this author on:Simon Thomas;Simon ThomasCyprotex Discovery Limited15 Beech LaneMacclesfield, CheshireSK10 2DRUKSearch for other works by this author on:Simone Stahl;Simone StahlDMPK DSM, iMED and Early DevelopmentAstraZeneca R&D310 Darwin BuildingCambridge Science Park, Milton RoadCambridgeCB4 0WGUK[email protected]Search for other works by this author on:Constanze Hilgendorf;Constanze HilgendorfDMPK DSM, iMED and Early DevelopmentAstraZeneca R&DPepparedsleden 1Mölndal431 83SwedenSearch for other works by this author on:Katherine FennerKatherine FennerDMPK DSM, iMED and Early DevelopmentAstraZeneca R&D310 Darwin BuildingCambridge Science Park, Milton RoadCambridgeCB4 0WGUK[email protected]Search for other works by this author on:
-
Chapter 8: Knockout and Humanised Animal Models to Study Membrane Transporters in Drug Developmentp298-332ByLaurent Salphati;Laurent SalphatiGenentech, Inc.1 DNA WaySouth San FranciscoCA 94080USASearch for other works by this author on:Maciej J. Zamek-GliszczynskiMaciej J. Zamek-GliszczynskiGlaxoSmithKline5 Moore DriveResearch Triangle ParkNC 27709USASearch for other works by this author on:
-
Chapter 9: Mechanistic Modelling to Predict Transporter-mediated Drug Disposition and Drug–Drug Interactionsp333-360ByRui Li;Rui LiSystems Modeling and Simulation, Pharmacokinetics, Dynamics and Metabolism, Worldwide Research and Development, Pfizer Inc.610 Main StreetCambridgeMA 02139USASearch for other works by this author on:Krishna K. Machavaram;Krishna K. MachavaramSimcyp Limited (a Certara Company), Blades Enterprise CentreJohn StreetSheffieldS2 4SUUKSearch for other works by this author on:Simon Thomas;Simon ThomasScientific Computing Group, Cyprotex Discovery Ltd15 Beech LaneMacclesfieldSK10 2DRUKSearch for other works by this author on:Manthena V. VarmaManthena V. VarmaPharmacokinetics, Dynamics and Metabolism, Worldwide Research and Development, Pfizer Inc.Eastern Point RoadGrotonCT 06340USA[email protected]Search for other works by this author on:
-
Chapter 10: Transporter Drug–Drug Interactions: A Pharmaceutical Industry Perspectivep361-417BySilke Simon;Silke SimonPharmaceutical Sciences, Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche LtdBaselSwitzerland[email protected]Search for other works by this author on:Mohammed Ullah;Mohammed UllahPharmaceutical Sciences, Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche LtdBaselSwitzerland[email protected]Search for other works by this author on:Robert van Waterschoot;Robert van WaterschootPharmaceutical Sciences, Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche LtdBaselSwitzerland[email protected]Search for other works by this author on:Dietmar Schwab;Dietmar SchwabClinical Pharmacology, Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche LtdBaselSwitzerlandSearch for other works by this author on:Susan Grange;Susan GrangeClinical Pharmacology, Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche LtdBaselSwitzerlandSearch for other works by this author on:Caroline A. Lee;Caroline A. LeeArdea Biosciences, Inc.San DiegoCAUSASearch for other works by this author on:Christoph FunkChristoph FunkPharmaceutical Sciences, Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche LtdBaselSwitzerland[email protected]Search for other works by this author on:
-
Chapter 11: Transporter Drug–Drug Interactions: Regulatory Requirements and Drug Labellingp418-449ByGustav Ahlin;Gustav AhlinMPAP.O. Box 26, SE-751 03 UppsalaSwedenSearch for other works by this author on:Naomi Nagai;Naomi NagaiPMDAShin-Kasumigaseki Building, 3-3-2 KasumigasekiChiyoda-ku, Tokyo 100-0013JapanSearch for other works by this author on:Daisuke Iwata;Daisuke IwataPMDAShin-Kasumigaseki Building, 3-3-2 KasumigasekiChiyoda-ku, Tokyo 100-0013JapanSearch for other works by this author on:Masanobu Sato;Masanobu SatoPMDAShin-Kasumigaseki Building, 3-3-2 KasumigasekiChiyoda-ku, Tokyo 100-0013JapanSearch for other works by this author on:Kenta YoshidaKenta YoshidaORISE fellow, FDA/CDER/OTS/OCP10903 New Hampshire AvenueSilver SpringMD20993USASearch for other works by this author on:
Spotlight
Advertisement
Advertisement